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ABSTRACT  
This study was designed to identify mechanisms responsible for coronary vasodilation in 
response to progressive decreases in hematocrit. Isovolemic hemodilution was produced in open-
chest, anesthetized swine via concurrent removal of 500 ml of arterial blood and the addition of 
500 ml of 37°C saline or synthetic plasma expander (Hespan, 6% hetastarch in 0.9% sodium 
chloride). Progressive hemodilution with Hespan resulted in an increase in coronary flow from 
0.39 ± 0.05 to 1.63 ± 0.16 ml/min/g (P < 0.001) as hematocrit was reduced from 32 ± 1% to 10 ± 
1% (P < 0.001). Overall, coronary flow corresponded with the level of myocardial oxygen 
consumption, was dependent on arterial pressures ≥ ~60 mmHg, and occurred with little/no 
change in coronary venous PO2. Anemic coronary vasodilation was unaffected by the inhibition 
of nitric oxide synthase (L-NAME: 25 mg/kg iv; P = 0.92) or voltage-dependent K+ (KV) channels 
(4-aminopyridine: 0.3 mg/kg iv; P = 0.52). However, administration of the KATP channel antagonist 
(glibenclamide: 3.6 mg/kg iv) resulted in an ~40% decrease in coronary blood flow (P < 0.001) as 
hematocrit was reduced to ~10%. These reductions in coronary blood flow corresponded with 
significant reductions in myocardial oxygen delivery at baseline and throughout isovolemic 
anemia (P < 0.001). These data indicate that vasodilator factors produced in response to 
isovolemic hemodilution converge on vascular smooth muscle glibenclamide-sensitive (KATP) 
channels to maintain myocardial oxygen delivery and that this response is not dependent on 
endothelial-derived nitric oxide production or pathways that mediate dilation via KV channels. 
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INTRODUCTION 
The coronary circulation is tightly regulated in order to ensure adequate matching between 
myocardial oxygen delivery and metabolism. This control of coronary blood flow is essential as 
the myocardium extracts ~70-80 percent of the oxygen delivered while at rest [18, 19, 40, 50]. 
Thus, any physiologic perturbation that alters the overall balance between oxygen delivery and 
myocardial oxygen consumption (MVO2) requires the subsequent modulation of coronary 
microvascular resistance to ensure oxygen supply/demand balance. As such, the coronary 
circulation has a remarkable ability to increase blood flow upwards of 10-fold (from ~0.5 ml/min/g 
at rest to ≥ 5.0 ml/min/g with maximal dilation) [63]. Although this intricate coupling has been 
recognized for many years, our understanding of the underlying mechanisms remains rather 
limited.  
Prior studies to examine the balance between coronary blood flow and MVO2 have 
established that coronary blood flow increases exponentially (>4-fold) with ~70% reductions in 
arterial oxygen content in response to hemodilution (anemia), hypoxemia, and carbon monoxide 
poisoning [9, 29, 36, 37, 39, 43, 54, 64, 66, 71]. This progressive augmentation of coronary flow 
maintains overall myocardial oxygen delivery and occurs with a ~2-fold increase in MVO2 and 
little/no change in myocardial oxygen extraction [10, 19, 34, 35, 47, 64, 67, 68]. However, 
evidence of enhanced myocardial lactate release and impairments to both sub-endocardial blood 
flow and cardiac contractile function have been reported with more severe reductions in 
hematocrit (≤ 10%) [1, 3, 37, 45, 64]. Earlier studies have suggested a role for reduced blood 
viscosity in the coronary response to anemia [5, 31, 33, 46, 62]. However, data demonstrating 
diminished vasodilator reserve to hemodilution in the presence of a critical coronary stenosis or 
in response to a brief coronary occlusion (i.e. reactive hyperemia) directly implicate that 
progressive reductions in hematocrit lead to the activation of vasodilator pathways [7, 9, 22, 31, 
37, 67]. Nonetheless, elucidation of the mechanisms responsible for anemic coronary vasodilation 
has proven challenging. In particular, circulating catecholamine concentrations are not 
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significantly altered by reductions in hematocrit to ~9% [64] and consequently, increases in 
coronary blood flow observed during β-adrenoceptor blockade are sufficient to sustain myocardial 
oxygen delivery thereby reducing the likelihood that these effects are sympathetically mediated 
[11]. Inhibition of nitric oxide production with NG-nitro-L-arginine methyl ester (L-NAME) was also 
found to have little/no effect of the coronary blood flow in response to acute, euvolemic reductions 
in hematocrit from 40% to 20% [8]. However, whether nitric oxide contributes to the coronary 
dilator response as hematocrit is reduced below 20% has not been determined. Alternatively, 
end-effector K+ channels in vascular smooth muscle are regulated by a variety of influences 
including endogenous endothelial and metabolic factors [25], cellular energy status (ATP/ADP 
ratio) [13, 25, 48], redox-dependent signaling [53], and the overall degree of oxygenation [21, 28]. 
Yet, whether these channels contribute to the balance between myocardial oxygen delivery and 
metabolism in response to progressive hemodilution has not been determined. 
The purpose of this study was to identify mechanisms responsible for coronary 
vasodilation and the maintenance of myocardial oxygen delivery in response to moderate and 
severe reductions in hematocrit. Experiments were designed to test the hypothesis that the 
contributions of nitric oxide, voltage-dependent (KV), and/or ATP-sensitive (KATP) K+ channels 
progressively increase in response to acute isovolemic hemodilution in open-chest, anesthetized 
domestic swine. Our findings provide novel insight into the end-effector channels required for 
anemic coronary vasodilation. 
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METHODS 
All experiments involving animals were approved by an Institutional Animal Care and Use 
Committee and performed in accordance with the Guide for the Care and Use of Laboratory 
Animals (NIH Publication No. 85-23, Revised 2011). Lean adult male domestic swine (n = 29) 
were sedated with telazol, xylazine, and ketamine (5, 2.5, and 2.5 mg/kg) prior to anesthesia with 
morphine (0.5 mg/kg) and intravenous α-chloralose (60 mg/kg).  
 
Experimental preparation  
Anesthetized swine were intubated and ventilated with O2-supplemented room air. 
Femoral cut downs were performed and catheters placed in the femoral artery and vein for 
continuous measurement of systemic blood pressure and heart rate and for administration of 
anesthetic and antagonists, respectively. Succinylcholine (0.5 mg/kg) was administered prior to a 
thoracotomy in the left 5th intercostal space. The left anterior descending (LAD) coronary artery 
was isolated and a perivascular flow probe (Transonic Systems Inc.) placed around the artery. A 
catheter was placed in the interventricular vein to sample coronary venous blood. Systemic 
heparin (500 units/kg) was administered to prevent clotting in the coronary venous catheter. 
Following a ~15 min stabilization period, data were continuously recorded on IOX data acquisition 
software from EMKA Technologies (Falls Church, VA). 
 
Acute isovolemic anemia protocol  
Pigs were randomly assigned to one of the following six groups: 1) Control with saline 
replacement; 2) Control with Hespan (hydroxyethyl starch) replacement; 3) nitric oxide synthesis 
inhibition with nitro-L-arginine methyl ester (L-NAME, 25 mg/kg iv with Hespan replacement); 4) 
KV channel inhibition with 4-aminopyridine (4-AP, 0.3 mg/kg iv with Hespan replacement); 5) KATP 
channel inhibition glibenclamide (3.6 mg/kg with Hespan replacement); 6) glibenclamide vehicle 
(equal parts 95% ethanol, 1N NaOH, propylene glycol). Following administration of drugs (for 
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groups 3-6) and the ~15 min stabilization period of the animal, arterial and coronary venous blood 
samples were obtained at baseline and at stepwise serial reductions in hematocrit. Progressive 
isovolemic anemia was produced by withdrawing 500 ml of arterial blood that was simultaneously 
replaced by intravenous administration of 500 ml of saline or Hespan, which were warmed to 37°C 
prior to infusion. Following completion of experimental protocols, hearts were fibrillated and 
excised as recommended by the American Veterinary Medical Association Guide on Euthanasia.  
 
Blood gas analyses  
Arterial and coronary venous blood samples were collected, immediately sealed and 
placed on ice. The samples were analyzed for pH, PCO2, PO2, glucose, lactate, and oxygen 
content with an Instrumentation Laboratories automatic blood gas analyzer (GEM Premier 3000) 
and CO-oximeter (682) system. Hematocrit was determined by centrifugation of capillary tubes 
containing blood collected at each replacement on a StatSpin micro-hematocrit centrifuge 
(CritSpin M961-22). LAD perfusion territory was estimated to be 30% of total heart weight, as 
previously described by Feigl [20]. MVO2 was calculated by multiplying coronary blood flow by 
the arterial coronary venous difference in oxygen content.  
 
Statistical analysis  
Data are presented as mean ± SE. Statistical comparisons for data presented in Tables 
1 and 2 were made by a two-way analysis of variance (ANOVA; Factor A: drug treatment; Factor 
B: level of hematocrit). Experimental variables were averaged within and between animals relative 
to the following hematocrit levels: (≥ 28.0) → (27.9 – 22.0) → (21.9 – 17.0) → (16.9 – 11.0) → (≤ 
10.9). Differences were considered statistically significant when P < 0.05. If significance with 
ANOVA was detected, a Student–Newman–Keuls multiple comparison test was performed. The 
relationship between coronary blood flow and hematocrit was fit to an inverse, second-order 
equation for each animal and a statistical comparison (t-test) of the predicted coronary flow based 
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on the fit equation was performed at hematocrits of 10%, 20% and 30% to establish differences 
in relationships between treatments. Multiple linear regression analysis was used to compare 
slopes of response variables (oxygen delivery, coronary venous PO2) plotted vs. hematocrit or 
MVO2. If the slopes of the regression lines were not significantly different, an analysis of 
covariance (ANCOVA) was used to adjust response variables for linear dependence on 
hematocrit or MVO2. Statistical analyses were performed with Sigma Plot 11.0 software (Systat 
Software Inc., San Jose, CA, USA), ANCOVA analyses were performed with VassarStats 
(Arlington, New York, USA). 
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RESULTS 
Control responses to isovolemic hemodilution  
Hemodynamic and coronary responses to graded reductions in hematocrit in untreated 
control swine that received volume replacement with saline or the synthetic colloid Hespan 
(hydroxyethyl starch) are shown in Figure 1. Saline based isovolemic hemodilution produced 
significant decreases in blood pressure (from 74 ± 6 mmHg to 26 ± 2 mmHg; Figure 1A; P < 0.01) 
and MVO2 (from 61 ± 4 to 27 ± 4 ml O2/min/g; Figure 1B; P < 0.01). These reductions were 
associated with minimal change in coronary blood flow (0.49 ± 0.02 to 0.40 ± 0.06 ml/min/g; 
Figure 1C; P = 0.63) and marked decreases in myocardial oxygen delivery (78 ± 4 to 36 ± 6 ml 
O2/min/g; Figure 1D; P < 0.001) as hematocrit was reduced from ~35% to ~15%. In contrast, 
aortic blood pressure (Figure 1A) and MVO2 (Figure 1B) were not significantly altered by 
hemodilution in swine that received Hespan (Table 1). With the relative maintenance of blood 
pressure and MVO2, coronary blood flow increased ~4-fold as hematocrit was reduced to ≤10% 
(Figure 1C and Table 1). This increase in coronary blood flow was sufficient to maintain 
myocardial oxygen delivery at ~53 ± 5 µl O2/min/g (Figure 1D). However, examination of 
electrocardiograms revealed evidence of sub-endocardial ischemia (ST segment depression and 
T wave inversion) under these conditions (Figure 2). 
 Examination of coronary responses relative to changes in aortic pressure (i.e. coronary 
perfusion pressure), heart rate, and MVO2 are provided in Figure 3. These relationships 
demonstrate that coronary blood flow (Figure 3A) remained relatively constant over a wide range 
of blood pressures, down to ~40 mmHg, in swine that received saline replacement. However, 
myocardial oxygen delivery progressively decreased as aortic pressure fell with hemodilution in 
these animals (Figure 3B). In contrast, coronary vasodilation in response to isovolemic 
hemodilution in Hespan infused animals was not influenced by underlying changes in aortic 
pressure (Figure 3A) but was directly related to increases in heart rate (Figure 3C) and MVO2 
(Figure 3D). Interestingly, coronary venous PO2 remained unchanged with reductions in 
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hematocrit (Figure 3E; P = 0.97) and was unaffected by underlying differences in MVO2 in swine 
that received Hespan (Figure 3F; P = 0.90). In contrast, coronary venous PO2 decreased as 
MVO2 increased in swine that received saline replacement (Figure 3F; P < 0.01).  
 
Role of nitric oxide in anemic coronary vasodilation 
Inhibition of nitric oxide synthase with L-NAME resulted in a significant increase in mean 
arterial pressure from 92 ± 4 to 124 ± 6 mmHg (Table 1; P < 0.001) at baseline. This was 
associated with a significant increase in MVO2, from 41 ± 4 to 50 ± 5 µl O2/min/g (Table 1; P = 
0.013) at baseline. These effects of nitric oxide inhibition were evident throughout the isovolemic 
anemia protocol. Despite these hemodynamic effects, inhibition of nitric oxide did not affect 
coronary blood flow (Figure 4A; P = 0.36), myocardial oxygen delivery (Figure 4B; P = 0.92), or 
heart rate (Table 1; P = 0.521) as hematocrit was decreased from 32 ± 2% to 9 ± 1%. However, 
administration of L-NAME diminished coronary venous PO2 (Table 1; P = 0.002), primarily at 
higher hematocrits (Figure 4C; P < 0.01) and levels of MVO2 (Figure 4D; P = 0.03). 
 
Role of KV and KATP channels in anemic coronary vasodilation 
Blockade of KV channels with 4-AP did not significantly affect blood pressure (P = 0.097), 
heart rate (P = 0.195), or MVO2 (P = 0.38) as hematocrit was reduced from 33 ± 1% to 8 ± 1% 
(Table 1). Inhibition of KV channels also did not significantly alter coronary blood flow (Figure 5A; 
P = 0.21) or myocardial oxygen delivery (Figure 5B; P = 0.63) at baseline or in response to 
isovolemic anemia. In contrast, 4-AP significantly decreased coronary venous PO2 (Table 1; P < 
0.001) irrespective of underlying hematocrit (Figure 5C; P < 0.001) or MVO2 (Figure 5D; P < 
0.001). 
Inhibition of KATP channels with glibenclamide had no effect on blood pressure (P = 0.541) 
or heart rate (P = 0.139), however, MVO2 decreased ~35% relative to vehicle-control swine, 
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irrespective of underlying hematocrit (Table 2; P < 0.001). Administration of glibenclamide 
induced significant decreases in coronary blood flow (Table 2; P < 0.001) as hematocrit was 
reduced from 32 ± 1% to 9 ± 1% (Figure 6A; P < 0.001). These reductions in coronary blood flow 
corresponded with significant reductions in myocardial oxygen delivery at baseline and throughout 
isovolemic anemia (Figure 6B; P < 0.001). Glibenclamide also significantly decreased coronary 
venous PO2, (Table 2; Figure 6C; P = 0.003) but did not significantly alter the relationship 
between coronary venous PO2 and MVO2 (Figure 6D; P = 0.36). 
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DISCUSSION  
This investigation was designed to identify mechanisms responsible for coronary 
vasodilation and the maintenance of myocardial oxygen delivery in response to moderate and 
severe reductions in hematocrit. Experiments tested the hypothesis that the contribution of nitric 
oxide, KV, and/or KATP channels increase in response to acute isovolemic hemodilution in open-
chest, anesthetized domestic swine. Our findings are consistent with prior studies which have 
demonstrated that progressive augmentation of coronary blood flow in response to anemia is 
sufficient to maintain overall myocardial oxygen delivery, although subendocardial ischemia is 
apparent as hematocrit falls to ≤ 10% [1, 3, 37, 45, 64]. Overall, coronary blood flow corresponds 
with MVO2, is dependent on arterial driving pressures ≥ 60 mmHg, and occurs with little/no change 
in myocardial oxygen extraction (coronary venous PO2) [10, 19, 34, 35, 47, 64, 67, 68]. The major 
novel findings of this study are that inhibition of KATP channels with glibenclamide significantly 
attenuates anemic coronary vasodilation and that this response occurs independent of alterations 
in endothelial nitric oxide production or the activation of KV channels. These data are the first to 
implicate that vasodilator factors produced in response to graded reductions in hematocrit (arterial 
oxygen content) converge on vascular smooth muscle glibenclamide-sensitive KATP channels to 
mediate increases in coronary blood flow and maintain myocardial oxygen delivery.  
 
Myocardial Oxygen Supply/Demand Balance During Acute Isovolemic Anemia 
It is well established that reductions in hematocrit lead to marked hemodynamic responses 
including increases in cardiac output, heart rate, contractility, and MVO2 [8, 30, 37, 64], all of 
which are important determinants of coronary blood flow [25]. In the present study, we noted 
significant differences in the coronary response to hemodilution in swine that received volume 
replacement with saline vs Hespan. We propose that the lack of a change in coronary blood flow 
to progressive anemia in the saline group (Figure 1C) is most likely due to marked reductions in 
arterial pressure which fell beyond the normal autoregulatory range at relatively high (~30%) 
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hematocrits (Figure 1A; Figure 3A). These findings support that adequate coronary perfusion 
pressure (≥ 60 mmHg) is required to ensure the maintenance of myocardial oxygen delivery in 
response to progressive reductions in hematocrit. Importantly, when arterial pressure is 
maintained by volume replacement with Hespan, increases in coronary blood flow are directly 
related to the degree of hemodilution (Figure 1) and reductions in coronary vascular resistance. 
The central question surrounding this phenomenon is “how” changes in hematocrit induce 
increases in coronary blood flow precisely to the degree necessary to preserve myocardial oxygen 
delivery. 
The simplest explanation for reductions in coronary vascular resistance in response to 
anemia is a reduction of blood viscosity. While analysis of vascular hindrance 
(resistance/viscosity) supports a role for viscosity at hematocrits ranging from ~60% to 20% [33], 
studies which have documented diminished vasodilator reserve to hemodilution in the presence 
of a critical coronary stenosis or in response to a brief coronary occlusion (i.e. reactive hyperemia) 
directly demonstrate that progressive reductions in hematocrit lead to the activation of vasodilator 
pathways [7, 9, 22, 31, 37, 67]. We propose that the discrepant coronary responses to volume 
replacement with saline are not related to differences in the viscosity as the lower dynamic 
viscosity of saline vs. Hespan would be predicted to augment the overall degree of anemic 
coronary vasodilation. However, reductions in arterial pressure in swine that received saline 
confound interpretation of the role of viscosity.  
Although it is apparent that coronary vasodilation occurs in response to anemia, the 
mechanisms responsible for anemic coronary dilation have remained elusive. More specifically, 
how changes in hematocrit are sensed is simply not understood. Classically, changes in 
myocardial tissue PO2, which are indexed by changes in coronary venous PO2, are proposed to 
invoke the production of vasodilator factors that act to increase coronary blood flow and restore 
tissue PO2 to normal levels via negative feedback loop [25]. However, the consistency of coronary 
venous PO2 (myocardial oxygen extraction) as hematocrit is lowered to < 10% (Figure 3) has 
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been found in rats [69], dogs [7, 12, 37, 61], pigs [64], baboons [68], and humans [24] and directly 
argues against this traditional paradigm. How and why coronary venous PO2 remains unchanged, 
even during severe hemodilution when ischemia is evident, is still yet another mystery. Proposed 
mechanisms for this paradoxical response include the flow-limited diffusion of oxygen, alterations 
in oxygen binding properties of blood due to altered plasma protein and buffer content, and the 
diminished release of oxygen by erythrocytes due to reduced intracellular convection [37, 67]. 
 
Role for Nitric Oxide in Anemic Coronary Vasodilation 
 Nitric oxide is an endothelial-derived vasodilating factor whose release is stimulated by 
pharmacological agonists (e.g. acetylcholine and bradykinin) and mechanical stimulation of the 
endothelium via shear stress, pulsatile flow, and/or axial strain [4, 38, 58, 59]. Prior studies also 
indicate that nitric oxide is scavenged and transported by hemoglobin in the form of S-
nitrosohemoglobin [41, 57]. To examine the role of nitric oxide in the regulation of coronary blood 
flow during progressive reductions in hematocrit, we performed isovolemic hemodilution 
experiments in the absence and presence of the nitric oxide synthase blocker L-NAME. While the 
inhibition of nitric oxide production resulted in significant (> 25 mmHg) increases in blood pressure 
(Table 1) and increased myocardial oxygen extraction at higher hematocrits (>20%) (Figure 4C), 
L-NAME had essentially no effect on coronary blood flow (Figure 4A) or myocardial oxygen 
delivery (Figure 4B) at hematocrits ranging from ~30% to ~10%. These data are consistent with 
the prior studies by Crystal et al. in dogs which documented no effect of intracoronary L-NAME 
on anemic coronary vasodilation down to hematocrits of ~20% [8]. Importantly, the use of 
intracoronary L-NAME prevented changes in systemic blood pressure and thus argue against 
hypertension as a confounding influence in the present study. The lack of effect of either systemic 
or intracoronary L-NAME demonstrates that alterations in nitric oxide bioavailability or endothelial 
shear stress do not play a significant role in modulating coronary blood flow in response to 
progressive isovolemic hemodilution.  
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Role for K+ Channels in Anemic Coronary Vasodilation 
 K+ channels dominate membrane conductance of coronary vascular smooth muscle and 
serve as important end-effector mechanisms of endogenous and exogenous vasodilator 
compounds [17, 25]. In particular, KV channels have been shown to contribute to the control of 
coronary blood flow at rest, during increases in MVO2, and following a brief coronary artery 
occlusion [2, 16, 26, 27, 49, 53]. To test the hypothesis that anemic coronary vasodilation is 
mediated by endogenous factors that converge on KV channels, we performed isovolemic 
hemodilution experiments in the absence and presence of the non-selective KV channel inhibitor 
4-AP [51-53]. Similar to our results with L-NAME, we found that 4-AP diminished coronary venous 
PO2 primarily at higher hematocrits (≥ 20%) (Table 1; Figure 5C). However, inhibition of KV 
channels did not significantly influence anemic coronary vasodilation as 4-AP had no effect on 
coronary blood flow (Figure 5A), myocardial oxygen delivery (Figure 5B) in response to 
progressive hemodilution. Prior studies from our laboratory have documented that the 0.3 mg/kg 
dose used in this investigation is sufficient to significantly impair coronary vasodilation and the 
balance between myocardial oxygen delivery and metabolism in response to increases in MVO2 
and to a brief coronary artery occlusion [2, 16, 53]. These findings importantly demonstrate that 
4-AP significantly reduces coronary blood flow, under specific physiological conditions, and 
indicate that the vasodilator “metabolites” produced in response to progressive anemia are 
different than those produced in response to exercise or acute myocardial ischemia. While we 
cannot rule out potential effects of 4-AP on cardiomyocytes or other K+ channel subtypes, it is 
noteworthy that 4-AP did not produce any changes in the ECG or MVO2 (Table 1) and that similar 
doses of 4-AP do not significantly influence coronary vasodilation in response to the KATP channel 
agonist pinacidil [16]. Taken together, our findings do not support a requisite role for KV channels, 
or the pathways that converge on these channels, in mediating coronary vasodilation in response 
to hemodilution.  
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 KATP channels are highly expressed in coronary vascular smooth muscle and are known 
to be activated by cellular energetic state (ATP/ADP ratio), intracellular pH, and by 
pathophysiologic conditions such as hypoxia and ischemia [14, 17]. However, whether isovolemic 
hemodilution mediates coronary vasodilation via activation of KATP channels has not been 
previously investigated. Data from this study are the first to demonstrate that the inhibition of KATP 
channels with glibenclamide markedly diminishes increases in coronary blood flow (Figure 6A) 
and myocardial oxygen delivery (Figure 6B) in response to progressive reductions in hematocrit. 
It is important to point out that glibenclamide significantly decreased MVO2 by ~45-50% at all 
levels of hematocrit (Table 2) and that such reductions in MVO2 could result in decreases in 
coronary blood flow, possibly via effects on mitochondrial KATP channels [25]. However, we 
propose that this is likely not the case as the progressive reduction of the coronary blood flow 
response to decreases in hematocrit in glibenclamide treated swine (Figure 6A) does not 
correspond with augmented decreases in MVO2 (Table 2). Furthermore, the Bache laboratory 
previously documented that glibenclamide-mediated reductions in MVO2 are restored to normal 
levels by increasing coronary blood flow with intracoronary sodium nitroprusside [32]. This finding 
combined with additional evidence that the mitochondrial KATP channel antagonist 5-
hydroxydecanoate (5-HD) has no effect on MVO2 supports that glibenclamide-mediated 
decreases in MVO2 are the result of coronary vasoconstriction (limitation of myocardial oxygen 
delivery) rather than primary reductions in mitochondrial respiration per se [6]. However, we 
acknowledge that we cannot definitively rule out effects of glibenclamide on sarcolemmal or 
mitochondrial channels in cardiomyocytes and/or the potential for glibenclamide to antagonize 
other K+ channel subtypes (e.g. IK1 and KV1) [56, 70]. Despite the potential for these confounding 
influences, findings from this investigation directly support that anemia results in the production 
of factors that mediate coronary dilation via pathways that converge on glibenclamide-sensitive 
(KATP) channels.  
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The mechanisms responsible for the activation of KATP channels during hemodilution are 
yet to be determined. While prior studies indicate that hypoxia-induced hyperpolarization of 
vascular smooth muscle and vasodilation is diminished by glibenclamide [21], data from the 
Gutterman laboratory indicate that the direct vasodilator effect of hypoxia on isolated coronary 
arterioles occurs over a time period of 10-15 min [44]; i.e. development of smooth muscle hypoxia 
is unlikely to contribute to anemic coronary vasodilation. Evidence of overt myocardial ischemia 
(ST segment depression, T wave inversion, myocardial lactate release) and contractile 
dysfunction following more severe reductions in hematocrit (≤ 10%) implicates the activation of 
ischemic vasodilator pathways such as adenosine could be involved. This hypothesis is supported 
by earlier studies which have established that myocardial adenosine release increases 
exponentially with the severity of hypoxia [15, 29, 60, 65] and that the inhibition of adenosine 
receptors reduces hypoxic coronary vasodilation by ~20-25% [23, 42, 43, 55]. We propose that 
studies to examine the role of adenosine in response to progressive anemia should include 
inhibition of not only specific adenosine receptor subtypes (A1, A2A, A2B, and A3 receptors), but 
also involve experiments to interrogate the potential effects of other purine nucleotides (AMP, 
ADP), purinergic receptors (various P2Y subtypes), and potentially cyclooxygenase products. 
Furthermore, based on previous studies we hypothesize that unidentified factors (other than 
purinergic metabolites) are responsible for the majority (~75-80%) of anemic coronary 
vasodilation. 
 
IMPLICATIONS AND CONCLUSIONS 
 Data from this study highlight many unanswered questions that remain central to the field 
of coronary physiology. Namely, how alterations in myocardial oxygen supply and/or MVO2 are 
ultimately sensed and regulated. With regard to the coronary response to anemia, it is particularly 
intriguing that coronary blood flow increases precisely to the degree necessary to maintain oxygen 
delivery, and that this preservation occurs without a decrease in coronary venous PO2 (increase 
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in myocardial oxygen extraction). These findings indicate that reductions in myocardial tissue PO2 
are not required for maintaining myocardial oxygen supply/demand balance and suggest that 
other “oxygen sensing” mechanisms could be at play. While the present data do not provide 
evidence to support how progressive reductions in hematocrit are sensed, they do directly 
implicate a significant role for glibenclamide-sensitive (KATP) channels in the response. Whether 
the involvement of these channels occurs directly via changes in the energy status of vascular 
smooth muscle and/or through the production of vasoactive factors that converge on these 
channels remains to be determined. Importantly, our findings also demonstrate that the anemic 
coronary vasodilation is not dependent on endothelial-derived nitric oxide production or involve 
pathways that converge on smooth muscle KV channels. 
 
ACKNOWLEDGEMENTS 
The authors wish to thank Joshua Sturek for expert technical assistance. This study was 
supported by U01HL118738. 
 
CONFLICT OF INTEREST 
 The authors declare that they have no conflict of interest. 
  
Mechanisms of Anemic Coronary Vasodilation 
17 
 
REFERENCES 
1. Bagger H (1978) Distribution of maximum coronary blood flow in the left ventricular wall 
of anesthetized dogs. Acta Physiol Scand 104:48-60 doi:10.1111/j.1748-
1716.1978.tb06250.x 
 
2. Berwick ZC, Dick GM, Moberly SP, Kohr MC, Sturek M, Tune JD (2012) Contribution of 
voltage-dependent K(+) channels to metabolic control of coronary blood flow. J Mol Cell 
Cardiol 52:912-919 doi:10.1016/j.yjmcc.2011.07.004 
 
3. Brazier J, Cooper N, Buckberg G (1974) The adequacy of subendocardial oxygen delivery: 
the interaction of determinants of flow, arterial oxygen content and myocardial oxygen 
need. Circulation 49:968-977 doi:10.1161/01.CIR.49.5.968 
 
4. Canty JM, Jr., Schwartz JS (1994) Nitric oxide mediates flow-dependent epicardial 
coronary vasodilation to changes in pulse frequency but not mean flow in conscious dogs. 
Circulation 89:375-384 doi:10.1161/01.CIR.89.1.375 
 
5. Case RB, Berglund E, Sarnoff SJ (1955) Ventricular function. VII. Changes in coronary 
resistance and ventricular function resulting from acutely induced anemia and the effect 
thereon of coronary stenosis. Am J Med 18:397-405 doi:10.1016/0002-9343(55)90219-9 
 
6. Chen Y, Traverse JH, Zhang J, Bache RJ (2001) Selective blockade of mitochondrial 
K(ATP) channels does not impair myocardial oxygen consumption. Am J Physiol Heart 
Circ Physiol 281:H738-744  
 
7. Crystal GJ (1988) Coronary hemodynamic responses during local hemodilution in canine 
hearts. Am J Physiol 254:H525-531  
 
8. Crystal GJ, El-Orbany M, Zhou X, Salem MR, Kim SJ (2008) Hemodilution does not alter 
the coronary vasodilating effects of endogenous or exogenous nitric oxide. Can J Anaesth 
55:507-514 doi:10.1007/BF03016670 
 
9. Crystal GJ, Kim SJ, Salem MR (1993) Right and left ventricular O2 uptake during 
hemodilution and beta-adrenergic stimulation. Am J Physiol 265:H1769-1777  
 
10. Crystal GJ, Rooney MW, Salem MR (1988) Regional hemodynamics and oxygen supply 
during isovolemic hemodilution alone and in combination with adenosine-induced 
controlled hypotension. Anesth Analg 67:211-218 doi:10.1213/00000539-198803000-
00002 
 
11. Crystal GJ, Ruiz JR, Rooney MW, Salem MR (1988) Regional hemodynamics and oxygen 
supply during isovolemic hemodilution in the absence and presence of high-grade beta-
adrenergic blockade. J Cardiothorac Anesth 2:772-779 doi:10.1016/0888-
6296(88)90101-9 
 
12. Crystal GJ, Salem MR (1991) Myocardial and systemic hemodynamics during isovolemic 
hemodilution alone and combined with nitroprusside-induced controlled hypotension. 
Anesth Analg 72:227-237 doi:10.1213/00000539-199102000-00016 
 
Mechanisms of Anemic Coronary Vasodilation 
18 
 
13. Dart C, Standen NB (1995) Activation of ATP-dependent K+ channels by hypoxia in 
smooth muscle cells isolated from the pig coronary artery. J Physiol 483 ( Pt 1):29-39 
doi:10.1113/jphysiol.1995.sp020565 
 
14. Dart C, Standen NB (1993) Adenosine-activated potassium current in smooth muscle cells 
isolated from the pig coronary artery. J Physiol 471:767-786 
doi:10.1113/jphysiol.1993.sp019927 
 
15. Deussen A, Borst M, Kroll K, Schrader J (1988) Formation of S-adenosylhomocysteine in 
the heart. II: A sensitive index for regional myocardial underperfusion. Circ Res 63:250-
261 doi:10.1161/01.RES.63.1.250 
 
16. Dick GM, Bratz IN, Borbouse L, Payne GA, Dincer UD, Knudson JD, Rogers PA, Tune JD 
(2008) Voltage-dependent K+ channels regulate the duration of reactive hyperemia in the 
canine coronary circulation. Am J Physiol Heart Circ Physiol 294:H2371-2381 
doi:10.1152/ajpheart.01279.2007 
 
17. Dick GM, Tune JD (2010) Role of potassium channels in coronary vasodilation. Exp Biol 
Med (Maywood) 235:10-22 doi:10.1258/ebm.2009.009201 
 
18. Duncker DJ, Bache RJ (2008) Regulation of coronary blood flow during exercise. Physiol 
Rev 88:1009-1086 doi:10.1152/physrev.00045.2006 
 
19. Feigl EO (1983) Coronary physiology. Physiol Rev 63:1-205  
 
20. Feigl EO, Neat GW, Huang AH (1990) Interrelations between coronary artery pressure, 
myocardial metabolism and coronary blood flow. J Mol Cell Cardiol 22:375-390 
doi:10.1016/0022-2828(90)91474-L 
 
21. Gauthier-Rein KM, Bizub DM, Lombard JH, Rusch NJ (1997) Hypoxia-induced 
hyperpolarization is not associated with vasodilation of bovine coronary resistance 
arteries. Am J Physiol 272:H1462-1469  
 
22. Geha AS (1976) Coronary and cardiovascular dynamics and oxygen availability during 
acute normovolemic anemia. Surgery 80:47-53  
 
23. Gewirtz H, Olsson RA, Most AS (1987) Role of adenosine in mediating the coronary 
vasodilative response to acute hypoxia. Cardiovasc Res 21:81-89 doi:10.1093/cvr/21.2.81 
 
24. Gisselsson L, Rosberg B, Ericsson M (1982) Myocardial blood flow, oxygen uptake and 
carbon dioxide release of the human heart during hemodilution. Acta Anaesthesiol Scand 
26:589-591 doi:10.1111/j.1399-6576.1982.tb01820.x 
 
25. Goodwill AG, Dick GM, Kiel AM, Tune JD (2017) Regulation of Coronary Blood Flow. 
Compr Physiol 7:321-382 doi:10.1002/cphy.c160016 
 
26. Goodwill AG, Fu L, Noblet JN, Casalini ED, Sassoon D, Berwick ZC, Kassab GS, Tune 
JD, Dick GM (2016) KV7 channels contribute to paracrine, but not metabolic or ischemic, 
regulation of coronary vascular reactivity in swine. Am J Physiol Heart Circ Physiol 
310:H693-704 doi:10.1152/ajpheart.00688.2015 
 
Mechanisms of Anemic Coronary Vasodilation 
19 
 
27. Goodwill AG, Noblet JN, Sassoon D, Fu L, Kassab GS, Schepers L, Herring BP, Rottgen 
TS, Tune JD, Dick GM (2016) Critical contribution of KV1 channels to the regulation of 
coronary blood flow. Basic Res Cardiol 111:56 doi:10.1007/s00395-016-0575-0 
 
28. Guarini G, Kiyooka T, Ohanyan V, Pung YF, Marzilli M, Chen YR, Chen CL, Kang PT, 
Hardwick JP, Kolz CL, Yin L, Wilson GL, Shokolenko I, Dobson JG, Jr., Fenton R, Chilian 
WM (2016) Impaired coronary metabolic dilation in the metabolic syndrome is linked to 
mitochondrial dysfunction and mitochondrial DNA damage. Basic Res Cardiol 111:29 
doi:10.1007/s00395-016-0547-4 
 
29. Herrmann SC, Feigl EO (1992) Adrenergic blockade blunts adenosine concentration and 
coronary vasodilation during hypoxia. Circ Res 70:1203-1216 
doi:10.1161/01.RES.70.6.1203 
 
30. Hirose Y, Kimura H, Kitahata H, Kawahito S, Oshita S (2000) Nitric oxide does not play a 
major role in the regulation of systemic hemodynamic responses to acute normovolemic 
hemodilution. Acta Anaesthesiol Scand 44:96-100 doi:10.1034/j.1399-
6576.2000.440117.x 
 
31. Holtz J, Bassenge E, von Restoriff W, Mayer E (1976) Transmural differences in 
myocardial blood flow and in coronary dilatory capacity in hemodiluted conscious dogs. 
Basic Res Cardiol 71:36-46 doi:10.1007/BF01907781 
 
32. Ishibashi Y, Duncker DJ, Zhang J, Bache RJ (1998) ATP-sensitive K+ channels, 
adenosine, and nitric oxide-mediated mechanisms account for coronary vasodilation 
during exercise. Circ Res 82:346-359 doi:10.1161/01.RES.82.3.346 
 
33. Jan KM, Chien S (1977) Effect of hematocrit variations on coronary hemodynamics and 
oxygen utilization. Am J Physiol 233:H106-113  
 
34. Khouri EM, Gregg DE, Rayford CR (1965) Effect of exercise on cardiac output, left 
coronary flow and myocardial metabolism in the unanesthetized dog. Circ Res 17:427-
437 doi:10.1161/01.RES.17.5.427 
 
35. Kuramoto K, Matsushita S, Matsuda T, Mifune J, Sakai M, Iwasaki T, Shinagawa T, Moroki 
N, Murakami M (1980) Effect of hematocrit and viscosity on coronary circulation and 
myocardial oxygen utilization. Jpn Circ J 44:443-448 doi:10.1253/jcj.44.443 
 
36. Lee SC, Mallet RT, Shizukuda Y, Williams AG, Jr., Downey HF (1992) Canine coronary 
vasodepressor responses to hypoxia are attenuated but not abolished by 8-
phenyltheophylline. Am J Physiol 262:H955-960  
 
37. Levy PS, Kim SJ, Eckel PK, Chavez R, Ismail EF, Gould SA, Ramez Salem M, Crystal GJ 
(1993) Limit to cardiac compensation during acute isovolemic hemodilution: influence of 
coronary stenosis. Am J Physiol 265:H340-349  
 
38. Liu Y, Gutterman DD (2009) Vascular control in humans: focus on the coronary 
microcirculation. Basic Res Cardiol 104:211-227 doi:10.1007/s00395-009-0775-y 
 
 
Mechanisms of Anemic Coronary Vasodilation 
20 
 
39. Martinez RR, Setty S, Zong P, Tune JD, Downey HF (2005) Nitric oxide contributes to 
right coronary vasodilation during systemic hypoxia. Am J Physiol Heart Circ Physiol 
288:H1139-1146 doi:10.1152/ajpheart.01139.2003 
 
40. Maurice H. Laughlin RJK, Dirk J. Duncker, Robert J. Bache (1996) Control of Blood Flow 
to Cardiac and Skeletal Muscle During Exercise. Compr Physiol Handbook of Physiology, 
Exercise: Regulation and Integration of Multiple Systems:705-769 
doi:10.1002/cphy.cp120116 
 
41. McMahon TJ, Stamler JS (1999) Concerted nitric oxide/oxygen delivery by hemoglobin. 
Methods Enzymol 301:99-114 doi:10.1016/S0076-6879(99)01073-3 
 
42. Merrill GF, Downey HF, Jones CE (1986) Adenosine deaminase attenuates canine 
coronary vasodilation during systemic hypoxia. Am J Physiol 250:H579-583  
 
43. Merrill GF, Downey HF, Yonekura S, Watanabe N, Jones CE (1988) Adenosine 
deaminase attenuates canine coronary vasodilatation during regional non-ischaemic 
myocardial hypoxia. Cardiovasc Res 22:345-350 doi:10.1093/cvr/22.5.345 
 
44. Miura H, Wachtel RE, Loberiza FR, Jr., Saito T, Miura M, Nicolosi AC, Gutterman DD 
(2003) Diabetes mellitus impairs vasodilation to hypoxia in human coronary arterioles: 
reduced activity of ATP-sensitive potassium channels. Circ Res 92:151-158 
doi:10.1161/01.RES.0000052671.53256.49 
 
45. Murakami H, Kim SJ, Lee SC, Strete D, Downey HF (1990) Adenosine exacerbates 
ischemic myocardial injury during regional coronary hypoxemia in the dog. Jpn Heart J 
31:365-383 doi:10.1536/ihj.31.365 
 
46. Murray JF, Escobar E, Rapaport E (1969) Effects of blood viscosity on hemodynamic 
responses in acute normovolemic anemia. Am J Physiol 216:638-642  
 
47. Nelson RR, Gobel FL, Jorgensen CR, Wang K, Wang Y, Taylor HL (1974) Hemodynamic 
predictors of myocardial oxygen consumption during static and dynamic exercise. 
Circulation 50:1179-1189 doi:10.1161/01.CIR.50.6.1179 
 
48. Nichols CG, Lederer WJ (1991) Adenosine triphosphate-sensitive potassium channels in 
the cardiovascular system. Am J Physiol 261:H1675-1686  
 
49. Ohanyan V, Yin L, Bardakjian R, Kolz C, Enrick M, Hakobyan T, Kmetz J, Bratz I, Luli J, 
Nagane M, Khan N, Hou H, Kuppusamy P, Graham J, Fu FK, Janota D, Oyewumi MO, 
Logan S, Lindner JR, Chilian WM (2015) Requisite Role of Kv1.5 Channels in Coronary 
Metabolic Dilation. Circ Res 117:612-621 doi:10.1161/CIRCRESAHA.115.306642 
 
50. Richardson RS, Poole DC, Knight DR, Kurdak SS, Hogan MC, Grassi B, Johnson EC, 
Kendrick KF, Erickson BK, Wagner PD (1993) High muscle blood flow in man: is maximal 
O2 extraction compromised? J Appl Physiol (1985) 75:1911-1916  
 
51. Rogers PA, Chilian WM, Bratz IN, Bryan RM, Jr., Dick GM (2007) H2O2 activates redox- 
and 4-aminopyridine-sensitive Kv channels in coronary vascular smooth muscle. Am J 
Physiol Heart Circ Physiol 292:H1404-1411 doi:10.1152/ajpheart.00696.2006 
 
Mechanisms of Anemic Coronary Vasodilation 
21 
 
52. Rogers PA, Dick GM, Knudson JD, Focardi M, Bratz IN, Swafford AN, Jr., Saitoh S, Tune 
JD, Chilian WM (2006) H2O2-induced redox-sensitive coronary vasodilation is mediated 
by 4-aminopyridine-sensitive K+ channels. Am J Physiol Heart Circ Physiol 291:H2473-
2482 doi:10.1152/ajpheart.00172.2006 
 
53. Saitoh S, Zhang C, Tune JD, Potter B, Kiyooka T, Rogers PA, Knudson JD, Dick GM, 
Swafford A, Chilian WM (2006) Hydrogen peroxide: a feed-forward dilator that couples 
myocardial metabolism to coronary blood flow. Arterioscler Thromb Vasc Biol 26:2614-
2621 doi:10.1161/01.ATV.0000249408.55796.da 
 
54. Setty S, Zong P, Sun W, Tune JD, Downey HF (2008) Hypoxia-induced vasodilation in the 
right coronary circulation of conscious dogs: role of adrenergic activation. Auton Neurosci 
138:76-82 doi:10.1016/j.autneu.2007.10.004 
 
55. Shizukuda Y, Mallet RT, Lee SC, Downey HF (1992) Hypoxic preconditioning of ischaemic 
canine myocardium. Cardiovasc Res 26:534-542 doi:10.1093/cvr/26.5.534 
 
56. Song Y, Srinivas M, Belardinelli L (1996) Nonspecific inhibition of adenosine-activated K+ 
current by glibenclamide in guinea pig atrial myocytes. Am J Physiol 271:H2430-2437  
 
57. Stamler JS, Jia L, Eu JP, McMahon TJ, Demchenko IT, Bonaventura J, Gernert K, 
Piantadosi CA (1997) Blood flow regulation by S-nitrosohemoglobin in the physiological 
oxygen gradient. Science 276:2034-2037 doi:10.1126/science.276.5321.2034 
 
58. Stepp DW, Merkus D, Nishikawa Y, Chilian WM (2001) Nitric oxide limits coronary 
vasoconstriction by a shear stress-dependent mechanism. Am J Physiol Heart Circ 
Physiol 281:H796-803  
 
59. Stepp DW, Nishikawa Y, Chilian WM (1999) Regulation of shear stress in the canine 
coronary microcirculation. Circulation 100:1555-1561 doi:10.1161/01.CIR.100.14.1555 
 
60. Stumpe T, Schrader J (1997) Phosphorylation potential, adenosine formation, and critical 
PO2 in stimulated rat cardiomyocytes. Am J Physiol 273:H756-766  
 
61. Tarnow J, Eberlein HJ, Hess W, Schneider E, Schweichel E, Zimmermann G (1979) 
Hemodynamic interactions of hemodilution, anaesthesia, propranolol pretreatment and 
hypovolaemia. II: Coronary circulation. Basic Res Cardiol 74:123-130 
doi:10.1007/BF01907815 
 
62. Thorling EB, Erslev AJ (1968) The "tissue" tension of oxygen and its relation to hematocrit 
and erythropoiesis. Blood 31:332-343  
 
63. Tune JD (2014) Coronary Circulation. Morgan & Claypool Life Sciences, Williston, VT 
 
64. Van Woerkens EC, Trouwborst A, Duncker DJ, Koning MM, Boomsma F, Verdouw PD 
(1992) Catecholamines and regional hemodynamics during isovolemic hemodilution in 
anesthetized pigs. J Appl Physiol (1985) 72:760-769  
 
65. Van Wylen DG, Williams AG, Jr., Downey HF (1993) Interstitial purine metabolites and 
lactate during regional myocardial hypoxia. Cardiovasc Res 27:1498-1503 
doi:10.1093/cvr/27.8.1498 
Mechanisms of Anemic Coronary Vasodilation 
22 
 
66. Vatner SF, Higgins CB, Franklin D (1972) Regional circulatory adjustments to moderate 
and severe chronic anemia in conscious dogs at rest and during exercise. Circ Res 
30:731-740 doi:10.1161/01.RES.30.6.731 
 
67. von Restorff W, Hofling B, Holtz J, Bassenge E (1975) Effect of increased blood fluidity 
through hemodilution on coronary circulation at rest and during exercise in dogs. Pflugers 
Arch 357:15-24 doi:10.1007/BF00584541 
 
68. Wilkerson DK, Rosen AL, Sehgal LR, Gould SA, Sehgal HL, Moss GS (1988) Limits of 
cardiac compensation in anemic baboons. Surgery 103:665-670  
 
69. Woodson RD, Auerbach S (1982) Effect of increased oxygen affinity and anemia on 
cardiac output and its distribution. J Appl Physiol Respir Environ Exerc Physiol 53:1299-
1306  
 
70. Yao X, Chang AY, Boulpaep EL, Segal AS, Desir GV (1996) Molecular cloning of a 
glibenclamide-sensitive, voltage-gated potassium channel expressed in rabbit kidney. J 
Clin Invest 97:2525-2533 doi:10.1172/JCI118700 
 
71. Young SH, Stone HL (1976) Effect of a reduction in arterial oxygen content (carbon 
monoxide) on coronary flow. Aviat Space Environ Med 47:142-146  
 
  
Mechanisms of Anemic Coronary Vasodilation 
23 
 
  Hematocrit (%) 32 ± 1 26 ± 1 21 ± 1 16 ± 1 10 ± 1
  Sample size n = 6 n = 6 n = 5 n = 6 n = 6
  Arterial oxygen content (ml O2/dl) 14.7 ± 0.4 11.6 ± 0.2* 9.1 ± 0.2* 7.0 ± 0.1* 4.7 ± 0.1* N/A P < 0.001 N/A
  Coronary blood flow (ml/min/g) 0.39 ± 0.05 0.54 ± 0.06 0.79 ± 0.10* 1.02 ± 0.12* 1.63 ± 0.16* N/A P < 0.001 N/A
  Mean blood pressure (mmHg) 92 ± 3 89 ± 4 87 ± 4 84 ± 4 81 ± 5 N/A P = 0.400 N/A
  Heart rate (bpm) 64 ± 6 68 ± 7 82 ± 11 81 ± 7 93 ± 7 N/A P = 0.070 N/A
  Arterial pH 7.47 ± 0.03 7.51 ± 0.02 7.50 ± 0.02 7.51 ± 0.02 7.49 ± 0.01 N/A P = 0.563 N/A
  Coronary venous pH 7.40 ± 0.03 7.44 ± 0.02 7.44 ± 0.02 7.42 ± 0.04 7.44 ± 0.02 N/A P = 0.825 N/A
  Arterial pO2 (mmHg) 173 ± 23 177 ± 22 175 ± 25 173 ± 23 173 ± 24 N/A P = 1.000 N/A
  Coronary venous pO2 (mmHg) 19.4 ± 1.8 20.5 ± 1.4 19.5 ± 1.3 18.7 ± 1.7 19.2 ± 1.7 N/A P = 0.952 N/A
  MVO2 (μl O2/min/g) 41 ± 4 42 ± 5 50 ± 6 50 ± 5 55 ± 6 N/A P = 0.293 N/A
  Hematocrit (%) 32 ± 2 24 ± 1 19 ± 1 14 ± 1 9 ± 1
  Sample size n = 5 n = 5 n = 5 n = 4 n = 5
  Arterial oxygen content (ml O2/dl) 15.3 ± 0.3 11.2 ± 0.3* 8.9 ± 0.4* 6.7 ± 0.2* 4.9 ± 0.1* P = 0.851 P < 0.001 P = 0.326
  Coronary blood flow (ml/min/g) 0.42 ± 0.03 0.47 ± 0.02 0.72 ± 0.04* 1.10 ± 0.12* 1.63 ± 0.24* P = 0.921 P < 0.001 P = 0.958
  Mean blood pressure (mmHg) 124 ± 6† 130 ± 3† 122 ± 7† 117 ± 8† 116 ± 9† P < 0.001 P = 0.206 P = 0.925
  Heart rate (bpm) 65 ± 5 63 ± 7 75 ± 7 85 ± 6 84 ± 7 P = 0.521 P = 0.005 P = 0.900
  Arterial pH 7.52 ± 0.01 7.54 ± 0.03 7.49 ± 0.02 7.46 ± 0.02 7.44 ± 0.03 P = 0.702 P = 0.157 P = 0.079
  Coronary venous pH 7.45 ± 0.02 7.43 ± 0.01 7.42 ± 0.02 7.37 ± 0.03 7.37 ± 0.04 P = 0.230 P = 0.643 P = 0.250
  Arterial pO2 (mmHg) 195 ± 13 194 ± 15 190 ± 14 186 ± 21 185 ± 16 P = 0.241 P = 0.998 P = 0.999
  Coronary venous pO2 (mmHg) 16.8 ± 2.4 14.5 ± 2.7† 14.5 ± 1.7 14.7 ± 0.9 18.0 ± 0.7 P = 0.002 P = 0.831 P = 0.681
  MVO2 (μl O2/min/g) 50 ± 5 48 ± 4 56 ± 7 68 ± 8 66 ± 10 P = 0.013 P = 0.036 P = 0.868
  Hematocrit (%) 33 ± 1 25 ± 1 20 ± 1 14 ± 2 8 ± 1
  Sample size n = 5 n = 5 n = 4 n = 4 n = 5
  Arterial oxygen content (ml O2/dl) 15.1 ± 0.3 11.7 ± 0.4* 9.1 ± 0.3* 7.0 ± 0.3* 4.8 ± 0.2* P = 0.541 P < 0.001 P = 0.900
  Coronary blood flow (ml/min/g) 0.37 ± 0.05 0.52 ± 0.06 0.76 ± 0.08 0.98 ± 0.14* 1.52 ± 0.19* P = 0.524 P < 0.001 P = 0.993
  Mean blood pressure (mmHg) 90 ± 7 93 ± 7 89 ± 5 98 ± 6 91 ± 5 P = 0.097 P = 0.753 P = 0.546
  Heart rate (bpm) 68 ± 8 67 ± 5 71 ± 6 73 ± 6 77 ± 5 P = 0.195 P = 0.055 P = 0.625
  Arterial pH 7.55 ± 0.02† 7.53 ± 0.03 7.55 ± 0.01 7.51 ± 0.03 7.51 ± 0.03 P = 0.018 P = 0.847 P = 0.363
  Coronary venous pH 7.48 ± 0.03† 7.48 ± 0.02 7.47 ± 0.01 7.47 ± 0.01 7.46 ± 0.01 P = 0.022 P = 0.966 P = 0.785
  Arterial pO2 (mmHg) 176 ± 17 178 ± 15 183 ± 12 206 ± 14 205 ± 9 P = 0.267 P = 0.934 P = 0.899
  Coronary venous pO2 (mmHg) 15.7 ± 1.2 14.3 ± 1.5† 13.3 ± 2.0† 15.5 ± 1.8 16.0 ± 1.5 P < 0.001 P = 0.962 P = 0.815
  MVO2 (μl O2/min/g) 39 ± 3 47 ± 4 53 ± 3 56 ± 8 60 ± 13 P = 0.380 P = 0.049 P = 0.947
Drug Hematocrit Interaction
Control
L-NAME
Drug Hematocrit Interaction
4-AP
Drug Hematocrit Interaction
Table 1. Hemodynamic and coronary responses to graded reductions in hematocrit (Hespan 
replacement) in untreated control, L-NAME, and 4-AP treated swine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* = P < 0.05 vs. baseline hematocrit, same treatment. † = P < 0.05 vs. control, same level of 
hematocrit. 
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  Hematocrit (%) 29 ± 1 23 ± 1 18 ± 1 12 ± 1 8 ± 1
  Sample size n = 4 n = 3 n = 4 n = 3 n = 4
  Arterial oxygen content (ml O2/dl) 14.8 ± 0.5 11.4 ± 0.2* 8.7 ± 0.2* 6.4 ± 0.2* 4.6 ± 0.2* P = 0.176 P < 0.001 P = 0.755
  Coronary blood flow (ml/min/g) 0.53 ± 0.07 0.66 ± 0.07 1.01 ± 0.09* 1.45 ± 0.13*† 2.00 ± 0.17* P < 0.001 P < 0.001 P = 0.522
  Mean blood pressure (mmHg) 100 ± 4 98 ± 5 96 ± 5 100 ± 6† 98 ± 5† P < 0.001 P = 0.977 P = 0.799
  Heart rate (bpm) 69 ± 11 64 ± 2 75 ± 10 75 ± 6 83 ± 2 P = 0.419 P = 0.040 P = 0.911
  Arterial pH 7.47 ± 0.04 7.44 ± 0.04 7.44 ± 0.03 7.42 ± 0.02† 7.41 ± 0.01† P < 0.001 P = 0.673 P = 0.345
  Coronary venous pH 7.40 ± 0.04 7.38 ± 0.03 7.38 ± 0.02 7.37 ± 0.02 7.37 ± 0.02 P = 0.012 P = 0.931 P = 0.741
  Arterial pO2 (mmHg) 165 ± 29 159 ± 26 181 ± 20 127 ± 28 167 ± 14 P = 0.366 P = 0.623 P = 0.881
  Coronary venous pO2 (mmHg) 15.3 ± 1.7 14.8 ± 0.9† 15.8 ± 0.8 16.3 ± 0.9 19.9 ± 0.5* P = 0.003 P = 0.028 P = 0.293
  MVO2 (μl O2/min/g) 66 ± 6† 66 ± 5† 76 ± 8† 80 ± 5† 73 ± 3† P < 0.001 P = 0.433 P = 0.847
  Hematocrit (%) 32 ± 1 25 ± 1 19 ± 1 14 ± 1 9 ± 1
  Sample size n = 5 n = 5 n = 5 n = 5 n = 5
  Arterial oxygen content (ml O2/dl) 14.9 ± 0.4 11.7 ± 0.3* 9.0 ± 0.3* 7.0 ± 0.2* 4.6 ± 0.1* P = 0.217 P < 0.001 P = 0.932
  Coronary blood flow (ml/min/g) 0.30 ± 0.03‡ 0.40 ± 0.04‡ 0.57 ± 0.04*‡ 0.79 ± 0.05*‡ 1.12 ± 0.08*‡ P < 0.001 P < 0.001 P < 0.001
  Mean blood pressure (mmHg) 107 ± 7 102 ± 12 104 ± 10 102 ± 10 94 ± 10 P = 0.541 P = 0.933 P = 0.951
  Heart rate (bpm) 56 ± 7 61 ± 9 64 ± 6 70 ± 7 78 ± 7 P = 0.139 P = 0.101 P = 0.960
  Arterial pH 7.46 ± 0.04 7.40 ± 0.04 7.39 ± 0.03 7.39 ± 0.03 7.39 ± 0.03 P = 0.213 P = 0.419 P = 0.975
  Coronary venous pH 7.37 ± 0.04 7.33 ± 0.04 7.33 ± 0.04 7.33 ± 0.03 7.33 ± 0.03 P = 0.044 P = 0.782 P = 0.993
  Arterial pO2 (mmHg) 200 ± 31 209 ± 31 211 ± 30 218 ± 25‡ 224 ± 21 P = 0.005 P = 0.908 P = 0.832
  Coronary venous pO2 (mmHg) 10.8 ± 1.7‡ 12.2 ± 1.4 14.0 ± 1.5 15.0 ± 1.0 17.0 ± 1.1* P = 0.003 P = 0.002 P = 0.838
  MVO2 (μl O2/min/g) 42 ± 4‡ 43 ± 4‡ 45 ± 2‡ 50 ± 4‡ 44 ± 4‡ P < 0.001 P = 0.237 P = 0.913
Drug Hematocrit Interaction
Glibenclamide Vehicle
Glibenclamide
Drug Hematocrit Interaction
Table 2. Hemodynamic and coronary responses to graded reductions in hematocrit (Hespan 
replacement) in vehicle and glibenclamide treated swine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* = P < 0.05 vs. baseline hematocrit, same treatment. † = P < 0.05 vs. control, same level of 
hematocrit. ‡ = P < 0.05 vs. vehicle, same level of hematocrit. 
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Figure 1. Relationship between aortic blood pressure (A), myocardial oxygen consumption (B), 
coronary blood flow (C) and myocardial oxygen delivery (D) vs. hematocrit for control swine that 
received volume replacement with saline and Hespan.  
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Figure 2. Representative tracing of the effects of decreasing hematocrit on ECG and coronary 
blood flow over time in untreated control swine that received volume replacement with Hespan.  
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Figure 3. Relationship between coronary blood flow (A) and myocardial oxygen delivery (B) vs. 
aortic pressure, coronary blood flow vs heart rate (C) and myocardial oxygen consumption (D), 
and coronary venous oxygen partial pressure vs. hematocrit (E) and myocardial oxygen 
consumption (F) for control swine that received volume replacement with saline and Hespan. 
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Figure 4. Relationship between coronary blood flow (A), myocardial oxygen delivery (B), and 
coronary venous oxygen tension (C) vs. hematocrit and coronary venous oxygen tension vs. 
myocardial oxygen consumption (D) for control and L-NAME treated swine that received volume 
replacement with Hespan. 
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Figure 5. Relationship between coronary blood flow (A), myocardial oxygen delivery (B), and 
coronary venous oxygen tension (C) vs. hematocrit and coronary venous oxygen tension vs. 
myocardial oxygen consumption (D) for control and 4-AP treated swine that received volume 
replacement with Hespan. 
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Figure 6. Relationship between coronary blood flow (A), myocardial oxygen delivery (B), and 
coronary venous oxygen tension (C) vs. hematocrit and coronary venous oxygen tension vs. 
myocardial oxygen consumption (D) for vehicle and glibenclamide treated swine that received 
volume replacement with Hespan. 
 
 
 
